Published reports of imatinib in HES, CEL, and SM with eosinophilia
Author, year (reference no.) . | No. of patients treated with imatinib . | Disease . | Responses* . | Comments . |
|---|---|---|---|---|
| Schaller and Burkland, 2001 (169)† | 1 | HES | CR | Initial report; rapid hematologic remission on imatinib 100 mg/d |
| Gleich et al, 2002 (170)† | 5 | HES | 4 CR | IL-5 levels normal in responders |
| Ault et al, 2002 (167)† | 1 | HES | CR | Resolution of 70% eosinophilia in 18 d on imatinib 100 mg/d |
| Pardanani et al, 2003 (171)† | 7 | HES, Eos-CMD | 3 CR, 1 PR | IL-5 levels elevated in responders |
| Cortes et al, 2003 (172)† | 9 | HES | 4 CR | 3 responses at imatinib 100 mg mg/d; 1 response at 400 mg/d |
| Cools et al, 2003 (3) | 11 | HES/CEL | 9 CR | FIP1L1-PDGFRA fusion present in 5 of 9 responders |
| Klion et al, 2003 (175) | 7 | HES-MPD | 7 CR | Molecular remission in 5 of 6 patients tested for FIP1L1-PDGFRA after 1-12 mo of imatinib |
| Pardanani et al, 2003 (176) | 6 | SM with eosinophilia | 3 CR | Responders had FIP1L1-PDGFRA fusion and no D816V KIT mutation |
Author, year (reference no.) . | No. of patients treated with imatinib . | Disease . | Responses* . | Comments . |
|---|---|---|---|---|
| Schaller and Burkland, 2001 (169)† | 1 | HES | CR | Initial report; rapid hematologic remission on imatinib 100 mg/d |
| Gleich et al, 2002 (170)† | 5 | HES | 4 CR | IL-5 levels normal in responders |
| Ault et al, 2002 (167)† | 1 | HES | CR | Resolution of 70% eosinophilia in 18 d on imatinib 100 mg/d |
| Pardanani et al, 2003 (171)† | 7 | HES, Eos-CMD | 3 CR, 1 PR | IL-5 levels elevated in responders |
| Cortes et al, 2003 (172)† | 9 | HES | 4 CR | 3 responses at imatinib 100 mg mg/d; 1 response at 400 mg/d |
| Cools et al, 2003 (3) | 11 | HES/CEL | 9 CR | FIP1L1-PDGFRA fusion present in 5 of 9 responders |
| Klion et al, 2003 (175) | 7 | HES-MPD | 7 CR | Molecular remission in 5 of 6 patients tested for FIP1L1-PDGFRA after 1-12 mo of imatinib |
| Pardanani et al, 2003 (176) | 6 | SM with eosinophilia | 3 CR | Responders had FIP1L1-PDGFRA fusion and no D816V KIT mutation |
CR indicates complete hematologic remission; PR, partial hematologic remission; Eos-CMD, eosinophilia-associated chronic myeloproliferative disorder; HES-MPD, myeloproliferative variant of HES; and SM, systemic mastocytosis.
Refer to individual studies for response criteria.
FIP1L1-PDGFRA fusion not assessed.